PHASE I STUDY WITH BMS-986458 ALONE AND IN COMBINATION WITH ANTI-LYMPHOMA-4 AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMAS (R/R NHL)
Summary description of the study
This is a multicenter, open-label Phase 1 dose-finding study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics, as well as the preliminary efficacy of BMS-986458 alone and in combination with anti-lymphoma agents in participants with R/R NHL. The study consists of two parts: dose escalation (Part A) and dose expansion (Part B). In Part A, the safety and tolerability of BMS-986458 as monotherapy (Part A1) and in combination with Rituximab (Part A2) are investigated to establish the OBD(s) for dose expansion. In Part B, the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMS-986458 alone (Part B1) or in combination with anti-lymphoma agents (Part B2) are further investigated. One or more doses from Part A may be selected for further evaluation in Part B. Additional expansion cohorts, in which other combinations (Part B2) or selected patient groups (Part B3) are studied, may be considered by the sponsor upon recommendation of the SRC. The aim of Part A is to identify one or more safe and tolerable doses for further investigation in Part B. Part B aims to obtain additional safety and preliminary efficacy data on these doses for RP2D determination.
(BASEC)
Intervention under investigation
BMS-986458 will be administered orally starting from Day 1 of Cycle 1 in a 28-day cycle for up to 2 years, until clinically significant disease progression or unacceptable toxicity occurs, or until the participant/physician decides to discontinue treatment. Rituximab will be administered according to the package insert and standard practice of the institution at a fixed dose of 375 mg/m2 for a maximum of 6 infusions (Cycles 1–6, Day 1). Survival follow-up will last up to 3 years (156 weeks) from the first treatment. Participants may be enrolled in the study for up to 160 weeks (including screening, treatment, and follow-up).
(BASEC)
Disease under investigation
Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
(BASEC)
Main inclusion criteria: Participants ≥ 18 years with R/R NHL (including DLBCL [i.e., DLBCL, not otherwise specified (NOS), and diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements] and FL): · For R/R DLBCL (de novo) and FL 3b: after at least 2 prior lines of therapy (e.g., first-line combination chemotherapy with Rituximab, anthracycline, an alkylating agent, and steroids, and at least one additional treatment). · For R/R DLBCL (transformed lymphoma): after at least 2 prior lines of therapy, which must have been administered after transformation. · For R/R FL (except for FL 3b): after at least 2 prior lines of therapy and meeting treatment criteria at the time of enrollment in the study as assessed by the investigator. The participant must have measurable disease (defined by at least one FDG-avid lesion in FDG-avid disease and a two-dimensional measurable disease on cross-sectional imaging by computed tomography or magnetic resonance imaging with at least one lesion > 1.5 cm in the transverse diameter); additionally, a plan for pregnancy prevention must be accepted and followed. Main exclusion criteria: Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3; (BASEC)
Exclusion criteria
Key exclusion criteria: Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3; inability to comply with specified restrictions, precautions, and prohibited treatments; prior CAR-T, cereblon-modulating agents, or radiotherapy ≤ 4 weeks ago, systemic cancer treatment ≤ 5 half-lives or 4 weeks ago, allogeneic SCT ≤ 6 months ago, or autologous SCT ≤ 3 months before start of study intervention; any condition, including relevant acute or chronic diseases, active or uncontrolled infections, or abnormal laboratory findings, that places participants at unacceptable risk if they participate in the study; known or suspected central nervous system involvement. (BASEC)
Trial sites
Basel, Bellinzona, Geneva
(BASEC)
Sponsor
Dr. Carmen Lilla Bristol Myers Squibb SA Hinterbergstrasse 16 6312 Steinhausen carmen.lilla@bms.com +41 79 544 22 77
(BASEC)
Contact
Contact Person Switzerland
Dr. med. Fatime Krasniqi
0041612655074
Fatime.Krasniqi@clutterusb.chUniversity Hospital Basel- Oncology Petersgraben 4 4031 Basel
(BASEC)
Scientific Information
not available
Name of the authorising ethics committee (for multicentre studies, only the lead committee)
Ethics Committee northwest/central Switzerland EKNZ
(BASEC)
Date of authorisation
02.05.2024
(BASEC)
ICTRP Trial ID
not available
Official title (approved by ethics committee)
CA123-1000: A Phase 1, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination with Anti-lymphoma Agents in Participants with Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL) (BASEC)
Academic title
not available
Public title
not available
Disease under investigation
not available
Intervention under investigation
not available
Type of trial
not available
Trial design
not available
Inclusion/Exclusion criteria
not available
not available
Primary and secondary end points
not available
not available
Registration date
not available
Incorporation of the first participant
not available
Secondary sponsors
not available
Additional contacts
not available
Secondary trial IDs
not available
Results-Individual Participant Data (IPD)
not available
Further information on the trial
not available
Results of the trial
Results summary
not available
Link to the results in the primary register
not available